Revance’s acquisition by Crown Laboratories completed

Crown Laboratories announced the closing of its acquisition of Revance (RVNC) Therapeutics. Crown’s tender offer to acquire all of the issued and outstanding shares of common stock, par value 0.1c per share of Revance at a purchase price of $3.65 per Share, expired as scheduled on February 4 and was not further extended. 86,197,893 Shares were validly tendered and not properly withdrawn in the Offer, representing approximately 82.0% of the issued and outstanding Shares as of the Expiration Time. Following completion of the Offer, Crown completed the acquisition of Revance through the second-step merger. Revance’s common stock will be delisted from the NASDAQ Global Select Market and deregistered under the Securities Exchange Act of 1934.